Novartis presents new data in breast and prostate cancer at ESMO

Posted: August 30, 2022 at 2:32 am

Basel, August 30, 2022 — Novartis will showcase new data from across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2022 with over 35 accepted abstracts from Novartis-sponsored and investigator-initiated trials including new data in advanced breast cancer and metastatic castration-resistant prostate cancer.

Originally posted here:
Novartis presents new data in breast and prostate cancer at ESMO

Related Posts